Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis
Acta Pharmaceutica Sinica B
;
(6): 1274-1285, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-881198
ABSTRACT
Liver is the most common metastatic site for colorectal cancer (CRC), there is no satisfied approach to treat CRC liver metastasis (CRCLM). Here, we investigated the role of a polycomb protein BMI-1 in CRCLM. Immunohistochemical analysis showed that BMI-1 expression in liver metastases was upregulated and associated with T4 stage, invasion depth and right-sided primary tumor. Knockdown
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Acta Pharmaceutica Sinica B
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS